Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

39.26 +0.45 (+1.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021
Upgrades According to Stephens & Co., the prior rating for World Acceptance Corp (NASDAQ:... 
Via Benzinga
Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic
Roche Holding AG's (OTC: RHHBY) 1H 2021 sales increased by 8% Y/Y at constant exchange rates (CER) to CHF 30.7 billion as peak demand for COVID-19 tests helped... 
Via Benzinga
Exposures COVID-19
Panic Attack
The H1 rise in US markets was based on hope for an end to lockdowns. 
Via Talk Markets
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced updated data from the ongoing Phase 1/2 trial of SPK-8011 gene therapy in... 
Via Benzinga
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes
The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with... 
Via Benzinga
Exposures Product Safety
FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
From Genentech
Via Business Wire
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A... 
Via Benzinga
New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A
From Genentech
Via Business Wire
Biogen Stock And The Aduhelm Drama: Will It Really Treat Alzheimer's?
The fate of Biogen stock is now intricately tied to the success — or failure — of its controversial Alzheimer's treatment, Aduhelm. 
Via Investor's Business Daily
5 Stocks to Own for the Surge in Coronavirus Variants
Despite easing restrictions, COVID is going to be around a lot longer than many think. 
Via The Motley Fool
Exposures COVID-19
Yellow Card
The price of oil fell about 1% today. 
Via Talk Markets
Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159
Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2021
Upgrades For FB Financial Corp (NYSE: 
Via Benzinga
WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients
The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients... 
Via Benzinga
Exposures COVID-19
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ:... 
Via Benzinga
New Month And Half Year
Welcome to H2. In theory, if markets did well in H1 they tend to close the year up. 
Via Talk Markets
End Of June
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-... 
Via Benzinga
Exposures COVID-19
Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... 
Via Benzinga
Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder
The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder... 
Via Benzinga
FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19
The 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
From Genentech
Via Business Wire
Crazy Thursday
Today the US stock market went ballistic probably because of a higher joblessness level than expected. 
Via Talk Markets
Here's Why Arcus Biosciences Stock Is Rising Today
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise. 
Via The Motley Fool
Arcus Biosciences Rockets, But Vague Update In Cancer Study Divides Analysts
Arcus Biosciences offered a vague update on its lung cancer regimens Wednesday, but RCUS stock rocketed on Thursday. 
Via Investor's Business Daily
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.